A share price of Iovance Biotherapeutics Inc [IOVA] is currently trading at $2.05, up 13.89%. An important factor to consider is whether the stock is rising or falling in short-term value. The IOVA shares have gain 17.14% over the last week, with a monthly amount drifted -34.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on May 16, 2025, when UBS downgraded its rating to a Neutral but kept the price target unchanged to $2 for it. Previously, Truist downgraded its rating to Hold on May 12, 2025. On May 09, 2025, downgrade downgraded it’s rating to Mkt Perform. UBS started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 24, 2024. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $10 on July 29, 2024. Goldman started tracking with a Buy rating for this stock on November 20, 2023, and assigned it a price target of $12. In a note dated September 18, 2023, Barclays reiterated an Overweight rating on this stock and revised its target price from $40 to $18.
Iovance Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.64 and $12.51. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $2.05 at the most recent close of the market. An investor can expect a potential return of 95.12% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Trailing Twelve Months sales for Iovance Biotherapeutics Inc [NASDAQ:IOVA] were 212.68M which represents 6798.46% growth. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -1.88%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.89 points at the first support level, and at 1.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.13, and for the 2nd resistance point, it is at 2.21.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Iovance Biotherapeutics Inc [NASDAQ:IOVA] is 4.18. On the other hand, the Quick Ratio is 3.64, and the Cash Ratio is 1.4. Considering the valuation of this stock, the price to sales ratio is 3.22, the price to book ratio is 0.89.
Transactions by insiders
Recent insider trading involved Kirby Daniel Gordon, Chief Commercial Officer, that happened on Jun 05 ’25 when 30000.0 shares were purchased. Chief Regulatory Officer, Puri Raj K. completed a deal on May 23 ’25 to buy 5600.0 shares. Meanwhile, Interim CEO & General Counsel Vogt Frederick G bought 25000.0 shares on May 14 ’25.
